As Senior Vice President of Marketing & Commercial Strategy, Maggie Rougier-Chapman leads the company’s marketing and commercial planning efforts to drive global growth and patient impact by creating broader awareness and accelerating customer adoption of the PGDx elio™ product line. Ms. Rougier-Chapman is a strategic leader with deep domain expertise spanning the diagnostics, genomics and life science sectors. Over the past two decades, she has been delivering successful business growth for both large multinational and rapidly scaling companies through commercialization of genomic solutions for clinical and research use. Prior to PGDx, Ms. Rougier-Chapman served as Head, Oncology Product Management & Strategy at Invitae, having joined Invitae through the acquisition of ArcherDX, where she served as Executive Vice President, Commercial Operations. In this role, Ms. Rougier-Chapman prepared ArcherDX for a successful exit and integration by reshaping the company’s product management, marketing & sales operations to support revenue growth, companion diagnostic (CDx) program expansions and global product launches of NGS-based in vitro diagnostics for therapy selection and monitoring. Prior to that, she served as Vice President, Global Marketing, at Bionano Genomics, Inc., where she led marketing, product management, and branding for the company’s optical genome mapping technology. Ms. Rougier-Chapman also held sales & marketing leadership roles at Agilent Technologies’ Diagnostics & Genomics Division, as well as various commercial roles at Advanced Cell Diagnostics, Cogenics, Ribonomics, Incyte Genomics, and Stratagene. She holds an M.S. in Molecular Cancer Biology and a B.S. in Biology from Duke University.